A novel benzodioxole-containing inhibitor of Toxoplasma gondii growth alters the parasite cell cycle

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5438-5451

  Kamau, Edwin ^a   Meehan, Tracy ^a   Lavine, Mark D ^b   Arrizabalaga, Gustavo ^b   Wilson, Gabriela Mustata ^c   Boyle, Jon ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF IDAHO   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; ANTIPARASITIC AGENT; MOLECULAR SCAFFOLD;

ARTICLE; CELL CYCLE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; DRUG ACTIVITY; ENZYME RELEASE; GROWTH INHIBITION; HOST CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TOXOPLASMA GONDII;

AMINO ACID SEQUENCE; ANIMALS; ANTIPARASITIC AGENTS; BENZODIOXOLES; CELL CYCLE; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARASITIC SENSITIVITY TESTS; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ALIGNMENT; TOXOPLASMA;

EID: 81555206769     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00455-11     Document Type: Article

References (55)

1. ACD Labs. 2009, posting date. ADME/TOX boxes. http://www.acdlabs.com.
2. Austeng, M. E., et al. 2010. Maternal infection with Toxoplasma gondii in pregnancy and the risk of hearing loss in the offspring. Int. J. Audiol. 49:65-68.
3. Bahl, A., et al. 2010. A novel multifunctional oligonucleotide microarray for Toxoplasma gondii. BMC Genomics 11:603.
4. Bardelle, C., et al. 2010. Inhibitors of the tyrosine kinase EphB4. 3. Identification of non-benzodioxole-based kinase inhibitors. Bioorg. Med. Chem. Lett. 20:6242-6245.
5. Bardelle, C., et al. 2008. Inhibitors of the tyrosine kinase EphB4. 2. Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. Bioorg. Med. Chem. Lett. 18:5717-5721.
6. Bardelle, C., et al. 2008. Inhibitors of the tyrosine kinase EphB4. 1. Structure- based design and optimization of a series of 2,4-bis- anilinopyrimidines. Bioorg. Med. Chem. Lett. 18:2776-2780. (Pubitemid 351622047)
7. Becker, K., H. Jablonowski, and D. Haussinger. 1996. Sulfadiazine- associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine 75:185-194. (Pubitemid 26260236)
8. Behnke, M. S., et al. 2010. Coordinated progression through two subtranscriptomes underlies the tachyzoite cycle of Toxoplasma gondii. PLoS One 5:e12354.
9. Bertschy, S., et al. 2006. Discontinuation of maintenance therapy against Toxoplasma encephalitis in AIDS patients with sustained response to antiretroviral therapy. Clin. Microbiol. Infect. 12:666-671. (Pubitemid 43842488)
10. Boothroyd, J. C., and J. F. Dubremetz. 2008. Kiss and spit: the dual roles of Toxoplasma rhoptries. Nat. Rev. Microbiol. 6:79-88. (Pubitemid 350286222)
11. Bordoli, L., et al. 2009. Protein structure homology modeling using SWISSMODEL workspace. Nat. Protoc. 4:1-13.
12. Boutros, P. C., et al. 2011. Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol. Appl. Pharmacol. 251:119-129.
13. Bowie, J. U., R. Luthy, and D. Eisenberg. 1991. A method to identify protein sequences that fold into a known three-dimensional structure. Science 253:164-170. (Pubitemid 21917131)
14. Castillo-Davis, C. I., and D. L. Hartl. 2003. GeneMerge-post-genomic analysis, data mining, and hypothesis testing. Bioinformatics 19:891-892. (Pubitemid 36582407)
15. Catalano-Pons, C., et al. 2004. Sulfadiazine-induced nephrolithiasis in children. Pediatr. Nephrol. 19:928-931. (Pubitemid 39144781)
16. Cory, A. H., T. C. Owen, J. A. Barltrop, and J. G. Cory. 1991. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3:207-212.
17. Darde, M. L. 2008. Toxoplasma gondii, "new" genotypes and virulence. Parasite 15:366-371.
18. Demar, M., et al. 2007. Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. Clin. Infect. Dis. 45:e88-e95. (Pubitemid 47580397)
19. Derouin, F., H. Pelloux, and ESCMID Study Group on Clinical Parasitology. 2008. Prevention of toxoplasmosis in transplant patients. Clin. Microbiol. Infect. 14:1089-1101.
20. Diani-Moore, S., et al. 2010. Identification of the aryl hydrocarbon receptor target gene TIPARP as a mediator of suppression of hepatic gluconeogenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin and of nicotinamide as a corrective agent for this effect. J. Biol. Chem. 285:38801-38810.
21. Di Carlo, P., A. Romano, M. G. Schimmenti, A. Mazzola, and L. Titone. 2008. Materno-fetal Toxoplasma gondii infection: critical review of available diagnostic methods. Infezioni Med. 16:28-32. (Pubitemid 351518466)
22. Donald, R. G., D. Carter, B. Ullman, and D. S. Roos. 1996. Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthinexanthine- guanine phosphoribosyltransferase gene. Use as a selectable marker for stable transformation. J. Biol. Chem. 271:14010-14019.
23. Dunning, M. J., N. L. Barbosa-Morais, A. G. Lynch, S. Tavare, and M. E. Ritchie. 2008. Statistical issues in the analysis of Illumina data. BMC Bioinformatics 9:85.
24. El Hajj, H., et al. 2006. The ROP2 family of Toxoplasma gondii rhoptry proteins: proteomic and genomic characterization and molecular modeling. Proteomics 6:5773-5784. (Pubitemid 44764014)
25. El Hajj, H., et al. 2007. ROP18 is a rhoptry kinase controlling the intracellular proliferation of Toxoplasma gondii. PLoS Pathog. 3:e14.
26. Gautier, L., L. Cope, B. M. Bolstad, and R. A. Irizarry. 2004. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315. (Pubitemid 38262761)
27. Guha, R., et al. 2006. The Blue Obelisk-interoperability in chemical informatics. J. Chem. Infect. Model. 46:991-998.
28. Holliday, J. D., C. Y. Hu, and P. Willett. 2002. Grouping of coefficients for the calculation of inter-molecular similarity and dissimilarity using 2D fragment bit-strings. Comb. Chem. High Throughput Screen. 5:155-166. (Pubitemid 34475167)
29. Irwin, J. J., and B. K. Shoichet. 2005. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Infect. Model. 45:177-182. (Pubitemid 40736970)
30. Jain, A. N. 2000. Morphological similarity: a 3D molecular similarity method correlated with protein-ligand recognition. J. Comput. Aided Mol. Des. 14:199-213. (Pubitemid 30110675)
31. Japertas, P., R. Didziapetris, and A. Petrauskas. 2003. Fragmental methods in the analysis of biological activities of diverse compound sets. Mini Rev. Med. Chem. 3:797-808.
32. Kiefer, F., K. Arnold, M. Kunzli, L. Bordoli, and T. Schwede. 2009. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 37:D387-D392.
33. Kongsaengdao, S., K. Samintarapanya, K. Oranratnachai, W. Prapakarn, and C. Apichartpiyakul. 2008. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. J. Int. Assoc. Physicians AIDS Care 7:11-16.
34. Labesse, G., et al. 2009. ROP2 from Toxoplasma gondii: a virulence factor with a protein-kinase fold and no enzymatic activity. Structure 17:139-146.
35. Laskowski, R. A., J. A. Rullmannn, M. W. MacArthur, R. Kaptein, and J. M. Thornton. 1996. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8:477-486. (Pubitemid 126706801)
36. Lavine, M. D., and G. Arrizabalaga. 2011. The antibiotic monensin causes cell cycle disruption of Toxoplasma gondii mediated through the DNA repair enzyme TgMSH-1. Antimicrob. Agents Chemother. 55:745-755.
37. Lipinski, C. A. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44:235-249. (Pubitemid 32239479)
38. Martin, Y. C., J. L. Kofron, and L. M. Traphagen. 2002. Do structurally similar molecules have similar biological activity? J. Med. Chem. 45:4350-4358. (Pubitemid 35025581)
39. Ojo, K. K., et al. 2010. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat. Struct. Mol. Biol. 17:602-607.
40. Peitsch, M. C. 1995. Protein modeling by email. Biotechnology 13:658-660.
41. Qiu, W., et al. 2009. Novel structural and regulatory features of rhoptry secretory kinases in Toxoplasma gondii. EMBO J. 28:969-979.
42. Ramachandran, G. N., C. Ramakrishnan, and V. Sasisekharan. 1963. Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 7:95-99.
43. Ramalingam, P., S. Ganapaty, and B. Rao Ch. 2010. In vitro antitubercular and antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones. Bioorg. Med. Chem. Lett. 20:406-408.
44. Saeij, J. P., et al. 2006. Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 314:1780-1783. (Pubitemid 44969090)
45. Schwede, T., J. Kopp, N. Guex, and M. C. Peitsch. 2003. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31:3381-3385. (Pubitemid 37442164)
46. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3:Article 3.
47. Taylor, S., et al. 2006. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 314:1776-1780. (Pubitemid 44969089)
48. Thomsen, R., and M. H. Christensen. 2006. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. 49:3315-3321. (Pubitemid 43830529)
49. Tsai, H. C., et al. 2002. Treatment of Toxoplasma brain abscess with clindamycin and sulfadiazine in an AIDS patient with concurrent atypical Pneumocystis carinii pneumonia. J. Formos. Med. Assoc. 101:646-649.
50. Vicente, E., P. R. Duchowicz, E. A. Castro, and A. Monge. 2009. QSAR analysis for quinoxaline-2-carboxylate 1,4-di-N-oxides as anti-mycobacterial agents. J. Mol. Graph. Model. 28:28-36.
51. Vicente, E., et al. 2008. Synthesis and structure-activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents. Eur. J. Med. Chem. 43:1903-1910.
52. Vicente, E., et al. 2009. Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem. 17:385-389.
53. Vicente, E., et al. 2008. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob. Agents Chemother. 52:3321-3326.
54. Wallqvist, A., R. Huang, N. Thanki, and D. G. Covell. 2006. Evaluating chemical structure similarity as an indicator of cellular growth inhibition. J. Chem. Infect. Model. 46:430-437. (Pubitemid 43282134)
55. Zheng, J., et al. 1993. A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. D Biol. Crystallogr. 49:362-365.